Operator
Ladies and gentlemen, thank you for standing by. Welcome to the Traws [Technical Difficulty].
[Operator Instructions]
As a reminder, this call is recorded. I would now like to turn the call over to John Fraunces, LifeSci Advisors.
John Fraunces
Lifesci Advisors, LLC
Thank you, operator, and welcome, everyone, to Traws Pharma’s Full Year 2025 Financial Results and Business Update Conference Call. This afternoon, Traws issued a press release reporting its 2025 financial results and provided a business update. If you have not yet seen this press release, it is available in the Investor Relations section of the company’s website. Following my introduction, we will hear from Traw’s Chief Executive Officer, Dr. Iain Dukes; and Chief Financial Officer, Charles Parker.
Before we begin, I would like to remind everyone that statements made during this conference call will include forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties that can cause actual results to differ materially. Forward-looking statements speak only as of the date they are made as the underlying facts and circumstances may change. Except as required by law, Traws disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances. For more information on forward-looking statements, please review the disclaimer in this morning’s press release and the risk factors in the company’s SEC filings.
With that, I will now turn the call over to Traws’s CEO, Dr. Iain Dukes.
Iain Dukes
CEO, Secretary & Director
Thanks, John, and thanks to everyone for joining us today. Over
